Ranibizumab in retinopathy of prematurity – one-year follow-up of ophthalmic outcomes and two-year follow-up of neurodevelopmental outcomes from the CARE-ROP study

PURPOSE: The primary endpoint results from the comparing alternative ranibizumab dosages for safety and effcacy in retinopathy of prematurity (CARE-ROP) core study identified ranibizumab as an effective treatment to control acute retinopathy of prematurity (ROP). This study reports the 1- and 2-year...

Descripción completa

Detalles Bibliográficos
Autores principales: Stahl, Andreas, Bründer, Marie-Christine, Lagrèze, Wolf A., Molnár, Fanni E., Barth, Teresa, Eter, Nicole, Guthoff, Rainer, Krohne, Tim U., Pfeil, Johanna M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9460412/
https://www.ncbi.nlm.nih.gov/pubmed/33742551
http://dx.doi.org/10.1111/aos.14852

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9460412/
https://www.ncbi.nlm.nih.gov/pubmed/33742551
http://dx.doi.org/10.1111/aos.14852

Ejemplares similares